share_log

MIRA Pharmaceuticals | 8-K: Current report

SEC ·  Mar 4 13:01

Summary by Futu AI

MIRA Pharmaceuticals has secured regulatory approval from the Israeli Ministry of Health and IRB to commence a Phase 1 clinical trial for Ketamir-2, their novel oral ketamine analog targeting neuropathic pain. The trial will be conducted at Hadassah Medical Center in Jerusalem, with recruitment starting in Q1 2025.The randomized, double-blind, placebo-controlled study aims to assess safety, tolerability, and pharmacokinetics of single and multiple ascending doses in healthy adult volunteers. The company awaits neurotoxicity study results, required by FDA, expected by Q2 2025, which should not affect the planned development timeline.MIRA anticipates completing Phase 1 by Q4 2025 and plans to initiate a Phase 2a study in neuropathic pain patients by year-end.
MIRA Pharmaceuticals has secured regulatory approval from the Israeli Ministry of Health and IRB to commence a Phase 1 clinical trial for Ketamir-2, their novel oral ketamine analog targeting neuropathic pain. The trial will be conducted at Hadassah Medical Center in Jerusalem, with recruitment starting in Q1 2025.The randomized, double-blind, placebo-controlled study aims to assess safety, tolerability, and pharmacokinetics of single and multiple ascending doses in healthy adult volunteers. The company awaits neurotoxicity study results, required by FDA, expected by Q2 2025, which should not affect the planned development timeline.MIRA anticipates completing Phase 1 by Q4 2025 and plans to initiate a Phase 2a study in neuropathic pain patients by year-end.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 382

Recommended